Johnson & Johnson, a global pharmaceutical company with cutting-edge capabilities in drug development and a history of successful academic collaborations, wishes to identify druggable targets in progressive fibrosing interstitial lung disease (PF‐ILD), idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH).
Jan
15
Comments are closed.